Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYLTAG phase II study of SYL040012 (bamosiran) vs timolol in open-angle glaucoma or ocular hypertension
2013-002947-27Phase 2Completed
- Sponsor
- Sylentis
- Start
- Jun 2014
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of bamosiran in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Sylentis. Primary endpoint: Change in mean diurnal intraocular pressure at Day 28. Started Jun 2014; status: completed.
02
Drugs
bamosiran
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2013-002947-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002947-27.